Dynavax Technologies (LTS:0IDA) ROCE % : 4.29% (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Dynavax Technologies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Dynavax Technologies's annualized ROCE % for the quarter that ended in Dec. 2024 was 4.29%.

Dynavax Technologies ROCE % Historical Data

The historical data trend for Dynavax Technologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dynavax Technologies ROCE % Chart

Dynavax Technologies Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-22.39

23.38

45.66

0.27

4.09

Dynavax Technologies Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															1.52	-4.33	6.93	8.73	4.29

Dynavax Technologies ROCE % Calculation

Dynavax Technologies's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	37.649	/	( ( (997.096 - 62.195)	+	(986.256 - 78.634) )	/ 2 )
	=	37.649	/	( (934.901	+	907.622)	/ 2 )
	=	37.649	/	921.2615
	=	4.09 %

Dynavax Technologies's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	40.784	/	( ( (1061.99 - 70.03)	+	(986.256 - 78.634) )	/ 2 )
	=	40.784	/	( ( 991.96	+	907.622 )	/ 2 )
	=	40.784	/	949.791
	=	4.29 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Dynavax Technologies (LTS:0IDA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Dynavax Technologies ROCE % Related Terms

Thank you for viewing the detailed overview of Dynavax Technologies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Dynavax Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dynavax Technologies Corp (LTS:0IDA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

DVAX:USA DYF1:Germany DYF1:Germany

Address

2100 Powell Street, Suite 720, Emeryville, CA, USA, 94608

Website

https://www.dynavax.com

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Dynavax Technologies Headlines

No Headlines